Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Homozygous mutations in the progranulin gene (GRN) are associated with neuronal ceroid lipofuscinosis 11 (CLN11), a rare lysosomal-storage disorder characterized by cerebellar ataxia, seizures, retinitis pigmentosa, and cognitive disorders, usually beginning between 13 and 25 years of age. This is a rare condition, previously reported in only four families. In contrast, heterozygous GRN mutations are a major cause of frontotemporal dementia associated with neuronal cytoplasmic TDP-43 inclusions. We identified homozygous GRN mutations in six new patients. The phenotypic spectrum is much broader than previously reported, with two remarkably distinct presentations, depending on the age of onset. A childhood/juvenile form is characterized by classical CLN11 symptoms at an early age at onset. Unexpectedly, other homozygous patients presented a distinct delayed phenotype of frontotemporal dementia and parkinsonism after 50 years; none had epilepsy or cerebellar ataxia. Another major finding of this study is that all GRN mutations may not have the same impact on progranulin protein synthesis. A hypomorphic effect of some mutations is supported by the presence of residual levels of plasma progranulin and low levels of normal transcript detected in one case with a homozygous splice-site mutation and late onset frontotemporal dementia. This is a new critical finding that must be considered in therapeutic trials based on replacement strategies. The first neuropathological study in a homozygous carrier provides new insights into the pathological mechanisms of the disease. Hallmarks of neuronal ceroid lipofuscinosis were present. The absence of TDP-43 cytoplasmic inclusions markedly differs from observations of heterozygous mutations, suggesting a pathological shift between lysosomal and TDP-43 pathologies depending on the mono or bi-allelic status. An intriguing observation was the loss of normal TDP-43 staining in the nucleus of some neurons, which could be the first stage of the TDP-43 pathological process preceding the formation of typical cytoplasmic inclusions. Finally, this study has important implications for genetic counselling and molecular diagnosis. Semi-dominant inheritance of GRN mutations implies that specific genetic counselling should be delivered to children and parents of CLN11 patients, as they are heterozygous carriers with a high risk of developing dementia. More broadly, this study illustrates the fact that genetic variants can lead to different phenotypes according to their mono- or bi-allelic state, which is a challenge for genetic diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low CSF and blood progranulin levels have been found in GRN mutation carriers with an almost 100% diagnostic accuracy.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · cited 6×
“Proband from family FTD-1042, and patients 1 and 2 from family FTDP-N12/1611, have developed behavioural and cognitive symptoms responding to the international clinical criteria of ‘probable’ bvFTD (Rascovsky et al., 2011).”
BackgroundMethodResultInfluentialClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058 · cited 3×
“nt mode of transmission. Most of them carry heterozygous pathogenic variants in C9orf72, GRN and MAPT genes. Among them, GRN (granulin precursor, OMIM *138945) is responsible for 20% of familial FTD (Baker et al., 2006; Cruts et al., 2006). GRN mutations lead to bvFTD or PPA phenotypes and, less frequently, to a corti…”
BackgroundInfluentialCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 4×
“It is well known that heterozygous GRN mutations lead to FTD (Cruts et al., 2006; Baker et al., 2006) but this is the first evidence that homozygous mutations may be evocated in the case of a bvFTD phenotype as well.”
BackgroundInfluentialA harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R. A., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. Y. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,017
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration
Lee, E. B., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3121 · Cited by 659 · cited 1×
“There is still a debate concerning whether TDP-43 induces neuronal loss by a toxic gain of function of cytoplasmic aggregates or by the loss of its normal function in the nucleus (Lee et al., 2012).”
BackgroundCommon variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions
Van Deerlin, V. M., Sleiman, P. M. A., Martinez-Lage, M., Chen-Plotkin, A., Wang, L.-S., Graff-Radford, N. R., Dickson, D. W., Rademakers, R., Boeve, B. F., Grossman, M., et al. (2010) · Nature Genetics · doi:10.1038/ng.536 · Cited by 579
Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin
Hu, F., Padukkavidana, T., Vægter, C. B., Brady, O. A., Zheng, Y., Mackenzie, I. R., Feldman, H. H., Nykjaer, A., & Strittmatter, S. M. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.034 · Cited by 536 · cited 1×
“Progranulin also plays a major role in lysosomes, where it is cleaved into granulins (Hu et al., 2010; Zhou et al., 2017a) and modulates proteins (beta-glucocerebrosidase, cathepsin D) involved in lysosomal disorders (Jian et al., 2016; Zhou et al., 2017b).”
BackgroundStrikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., Rossi, G., Pareyson, D., Mole, S. E., Staropoli, J. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.021 · Cited by 489
Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., Carmeliet, P., Van Den Bosch, L., & Robberecht, W. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200712039 · Cited by 418
Finch, N., Baker, M., Crook, R., Swanson, K., Kuntz, K., Surtees, R., Bisceglio, G., Rovelet-Lecrux, A., Boeve, B., Petersen, R. C., et al. (2009) · Brain · doi:10.1093/brain/awn352 · Cited by 386 · cited 1×
“cay (NMD). Progranulin is a secreted protein and thus, decreased or undetectable plasma progranulin levels are highly predictive of pathogenic heterozygous GRN mutations. Different thresholds of 110 (Finch et al., 2009), 74 (Ghidoni et al., 2008), or more recently 61 mg/l (Ghidoni et al., 2012; Galimberti et al., 2018…”
BackgroundLe Ber, I., Camuzat, A., Hannequin, D., Pasquier, F., Guedj, E., Rovelet-Lecrux, A., Hahn-Barma, V., van der Zee, J., Clot, F., Bakchine, S., et al. (2008) · Brain · doi:10.1093/brain/awn012 · Cited by 352
Self-citationLessons from non-canonical splicing
Sibley, C. R., Blazquez, L., & Ule, J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.46 · Cited by 316
Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury
Martens, L. H., Zhang, J., Barmada, S. J., Zhou, P., Kamiya, S., Sun, B., Min, S.-W., Gan, L., Finkbeiner, S., Huang, E. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63113 · Cited by 315 · cited 1×
“Progranulin has multiple functions as a neurotrophic factor and in neuroinflammation, two important biological pathways that contribute to neurodegeneration in progranulin-deficient models (Van Damme et al., 2008; Martens et al., 2012).”
Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration
Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M., & Binetti, G. (2008) · Neurology · doi:10.1212/01.wnl.0000325058.10218.fc · Cited by 299 · cited 1×
“, 2009), 74 (Ghidoni et al., 2008), or more recently 61 mg/l (Ghidoni et al.”
Ahmed, Z., Sheng, H., Xu, Y.-F., Lin, W.-L., Innes, A. E., Gass, J., Yu, X., Hou, H., Chiba, S., Yamanouchi, K., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090915 · Cited by 294 · cited 1×
“An overlap between FTD and CLN was previously shown in Grn-knockout mice, a model of GRN-related FTD that develops lysosomal vacuolization and lipofuscin accumulation (Ahmed et al., 2010).”
BackgroundTMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers
Finch, N., Carrasquillo, M. M., Baker, M., Rutherford, N. J., Coppola, G., DeJesus-Hernandez, M., Crook, R., Hunter, T., Ghidoni, R., Benussi, L., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0e3b · Cited by 243 · cited 1×
“Different thresholds of 110 (Finch et al., 2009), 74 (Ghidoni et al.”
BackgroundAnderson, G. W., Goebel, H. H., & Simonati, A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.014 · Cited by 227 · cited 1×
“more compact and formed a nearly complete circle (Figure 3C), instead of the classical aspect of curvilinear profiles which are uniformly curved, short, thin lamellar stacks of alternative dark and light lines with only minor variation in the degree of bending (Mole et al., 2011; Anderson et al., 2013).”
BackgroundThe Neuronal Ceroid-Lipofuscinoses (Batten Disease)
Mole, S. E., & Haltia, M. (2015) · Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease · doi:10.1016/b978-0-12-410529-4.00070-x · Cited by 220
Rademakers, R., Baker, M., Gass, J., Adamson, J., Huey, E. D., Momeni, P., Spina, S., Coppola, G., Karydas, A. M., Stewart, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70221-1 · Cited by 216 · cited 1×
“Age at onset in heterozygous GRN carriers ranges from 40 to 85 years (Rademakers et al., 2007; Le Ber et al., 2008).”
BackgroundClinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis
Mole, S. E., Anderson, G., Band, H. A., Berkovic, S. F., Cooper, J. D., Kleine Holthaus, S.-M., McKay, T. R., Medina, D. L., Rahim, A. A., Schulz, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30368-5 · Cited by 206
Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis
Ward, M. E., Chen, R., Huang, H.-Y., Ludwig, C., Telpoukhovskaia, M., Taubes, A., Boudin, H., Minami, S. S., Reichert, M., Albrecht, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5642 · Cited by 193
Vatsavayai, S. C., Yoon, S. J., Gardner, R. C., Gendron, T. F., Vargas, J. N. S., Trujillo, A., Pribadi, M., Phillips, J. J., Gaus, S. E., Hixson, J. D., et al. (2016) · Brain · doi:10.1093/brain/aww250 · Cited by 171 · cited 1×
“several years (Vatsavayai et al., 2016).”
Kufs Disease, the Major Adult Form of Neuronal Ceroid Lipofuscinosis, Caused by Mutations in CLN6
Arsov, T., Smith, K. R., Damiano, J., Franceschetti, S., Canafoglia, L., Bromhead, C. J., Andermann, E., Vears, D. F., Cossette, P., Rajagopalan, S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.04.004 · Cited by 164 · cited 1×
“A late-onset phenotype has been described previously for other forms of neuronal ceroid lipofuscinosis (Lauronen et al., 1999; van Diggelen et al., 2010; Xin et al., 2010; Arsov et al., 2011; Smith et al., 2013).”
BackgroundSenataxin: Genome Guardian at the Interface of Transcription and Neurodegeneration
Groh, M., Albulescu, L.-O., Cristini, A., & Gromak, N. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.021 · Cited by 139 · cited 1×
“clinical presentations (from pure to complex HSP for GRID2 and from cerebellar ataxia to amyotrophic lateral sclerosis for SETX), depending on the mono or bi-allelic genotype (Coutelier et al., 2015; Groh et al., 2017). The growing evidence that there is no strict ‘one gene, one disease’ relationship and that the same…”
BackgroundThe Neuronal Ceroid Lipofuscinoses (Batten Disease),
Koeppen, A. H. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00289-6 · Cited by 137
Progranulin Mutations as Risk Factors for Alzheimer Disease
Perry, D. C., Lehmann, M., Yokoyama, J. S., Karydas, A., Lee, J. J., Coppola, G., Grinberg, L. T., Geschwind, D., Seeley, W. W., Miller, B. L., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.393 · Cited by 133 · cited 1×
“All mutations identified here have been previously detected in the heterozygous state in FTD patients (Benussi et al., 2009; Almeida et al., 2014; Perry et al., 2013; Pottier et al., 2018) and one, p.”
BackgroundPottier, C., Zhou, X., Perkerson, R. B., Baker, M., Jenkins, G. D., Serie, D. J., Ghidoni, R., Benussi, L., Binetti, G., López de Munain, A., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30126-1 · Cited by 131 · cited 1×
“All mutations identified here have been previously detected in the heterozygous state in FTD patients (Benussi et al., 2009; Almeida et al., 2014; Perry et al., 2013; Pottier et al., 2018) and one, p.”
BackgroundCathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis
Smith, K. R., Dahl, H.-H. M., Canafoglia, L., Andermann, E., Damiano, J., Morbin, M., Bruni, A. C., Giaccone, G., Cossette, P., Saftig, P., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds558 · Cited by 130
Almeida, M. R., Macário, M. C., Ramos, L., Baldeiras, I., Ribeiro, M. H., & Santana, I. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.019 · Cited by 125
van Diggelen, O. P., Thobois, S., Tilikete, C., Zabot, M. T., Keulemans, J. L. M., van Bunderen, P. A., Taschner, P. E. M., Losekoot, M., & Voznyi, Y. V. (2001) · Annals of Neurology · doi:10.1002/ana.1103 · Cited by 118
Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
Jian, J., Tian, Q.-Y., Hettinghouse, A., Zhao, S., Liu, H., Wei, J., Grunig, G., Zhang, W., Setchell, K. D. R., Sun, Y., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.010 · Cited by 112 · cited 1×
“Progranulin also plays a major role in lysosomes, where it is cleaved into granulins (Hu et al., 2010; Zhou et al., 2017a) and modulates proteins (beta-glucocerebrosidase, cathepsin D) involved in lysosomal disorders (Jian et al., 2016; Zhou et al., 2017b).”
BackgroundLe Ber, I., the French research network on FTLD/FTLD-ALS, Camuzat, A., Guillot-Noel, L., Hannequin, D., Lacomblez, L., Golfier, V., Puel, M., Martinaud, O., Deramecourt, V., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121456 · Cited by 109 · cited 1×
“Repeat expansion in the C9orf72 gene was also ruled out for the two probands with the lateonset phenotype using a fluorescent repeat-primed PCR assay, as previously described (Le Ber et al., 2013).”
MethodSelf-citationProgranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide
Benussi, L., Ghidoni, R., Pegoiani, E., Moretti, D. V., Zanetti, O., & Binetti, G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.008 · Cited by 107 · cited 2×
“, 2012; Canafoglia et al., 2014; Almeida et al., 2016; Faber et al., 2017; Kamate et al., 2019). All mutations identified here have been previously detected in the heterozygous state in FTD patients (Benussi et al., 2009; Almeida et al., 2014; Perry et al., 2013; Pottier et al., 2018) and one, p.(Gln257Profs*27), in t…”
BackgroundGhidoni, R., Stoppani, E., Rossi, G., Piccoli, E., Albertini, V., Paterlini, A., Glionna, M., Pegoiani, E., Agnati, L. F., Fenoglio, C., et al. (2012) · Neurodegenerative Diseases · doi:10.1159/000333132 · Cited by 96 · cited 1×
“ctable plasma progranulin levels are highly predictive of pathogenic heterozygous GRN mutations. Different thresholds of 110 (Finch et al., 2009), 74 (Ghidoni et al., 2008), or more recently 61 mg/l (Ghidoni et al., 2012; Galimberti et al., 2018) have been established depending on the study. All heterozygous GRN mutat…”
Brandmeir, N. J., Geser, F., Kwong, L. K., Zimmerman, E. A., Qian, J., Lee, V. M. ‐., & Trojanowski, J. Q. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0315-5 · Cited by 96
Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses
Mukherjee, A. B., Appu, A. P., Sadhukhan, T., Casey, S., Mondal, A., Zhang, Z., & Bagh, M. B. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0300-6 · Cited by 96
Lauronen, L., Munroe, P. B., Järvelä, I. E., Autti, T. H., Mitchison, H. M., O'Rawe, A., Gardiner, R. M., Mole, S., Puranen, J., Häkkinen, A. ‐., et al. (1999) · Neurology · doi:10.1212/wnl.52.2.360 · Cited by 91 · cited 1×
“A late-onset phenotype has been described previously for other forms of neuronal ceroid lipofuscinosis (Lauronen et al., 1999; van Diggelen et al., 2010; Xin et al., 2010; Arsov et al., 2011; Smith et al., 2013).”
BackgroundRegulation of cathepsin D activity by the FTLD protein progranulin
Zhou, X., Paushter, D. H., Feng, T., Pardon, C. M., Mendoza, C. S., & Hu, F. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1719-5 · Cited by 89
Lysosomal processing of progranulin
Zhou, X., Paushter, D. H., Feng, T., Sun, L., Reinheckel, T., & Hu, F. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0205-9 · Cited by 85
GRID2 mutations span from congenital to mild adult-onset cerebellar ataxia
Coutelier, M., Burglen, L., Mundwiller, E., Abada-Bendib, M., Rodriguez, D., Chantot-Bastaraud, S., Rougeot, C., Cournelle, M.-A., Milh, M., Toutain, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001524 · Cited by 82 · cited 1×
“ult-onset) and distinct clinical presentations (from pure to complex HSP for GRID2 and from cerebellar ataxia to amyotrophic lateral sclerosis for SETX), depending on the mono or bi-allelic genotype (Coutelier et al., 2015; Groh et al., 2017). The growing evidence that there is no strict ‘one gene, one disease’ relati…”
BackgroundSelf-citationCLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL
Xin, W., Mullen, T. E., Kiely, R., Min, J., Feng, X., Cao, Y., O'Malley, L., Shen, Y., Chu-Shore, C., Mole, S. E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cff70d · Cited by 74 · cited 1×
“A late-onset phenotype has been described previously for other forms of neuronal ceroid lipofuscinosis (Lauronen et al., 1999; van Diggelen et al., 2010; Xin et al., 2010; Arsov et al., 2011; Smith et al., 2013).”
BackgroundCanafoglia, L., Morbin, M., Scaioli, V., Pareyson, D., D'Incerti, L., Fugnanesi, V., Tagliavini, F., Berkovic, S. F., & Franceschetti, S. (2014) · Epilepsia · doi:10.1111/epi.12632 · Cited by 71 · cited 6×
“been identified in five patients from four unrelated families (Smith et al., 2012; Canafoglia et al., 2014; Almeida et al., 2016; Faber et al., 2017; Kamate et al., 2019).”
BackgroundInfluentialGalimberti, D., Fumagalli, G. G., Fenoglio, C., Cioffi, S. M. G., Arighi, A., Serpente, M., Borroni, B., Padovani, A., Tagliavini, F., Masellis, M., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.016 · Cited by 58 · cited 1×
“lin levels are highly predictive of pathogenic heterozygous GRN mutations. Different thresholds of 110 (Finch et al., 2009), 74 (Ghidoni et al., 2008), or more recently 61 mg/l (Ghidoni et al., 2012; Galimberti et al., 2018) have been established depending on the study. All heterozygous GRN mutations are associated wi…”
BackgroundLattante, S., Ber, I. L., Galimberti, D., Serpente, M., Rivaud-Péchoux, S., Camuzat, A., Clot, F., Fenoglio, C., Scarpini, E. A., Brice, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.023 · Cited by 47
Self-citationNeuronal ceroid lipofuscinosis type-11 in an adolescent
Kamate, M., Detroja, M., & Hattiholi, V. V. (2019) · Brain and Development · doi:10.1016/j.braindev.2019.03.004 · Cited by 46
A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia
Faber, I., Prota, J. R. M., Martínez, A., Lopes‐Cendes, Í., & França, M. C. (2016) · European Journal of Neurology · doi:10.1111/ene.13194 · Cited by 32 · cited 4×
“More importantly, evidence that lysosomal dysfunction contributes to the pathological mechanisms of GRN came from the description of five CLN11 patients with homozygous mutations and symptoms of lysosomal storage disorders (Smith et al., 2012; Canafoglia et al., 2014; Almeida et al., 2016; Faber et al., 2017; Kamate e…”
BackgroundInfluentialAlmeida, M. R., Baldeiras, I., Ribeiro, M. H., Santiago, B., Machado, C., Massano, J., Guimarães, J., Resende Oliveira, C., & Santana, I. (2014) · Neurodegenerative Diseases · doi:10.1159/000352022 · Cited by 30
Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD
van der Zee, J., Mariën, P., Crols, R., Mossevelde, S. V., Dillen, L., Perrone, F., Engelborghs, S., Verhoeven, J., D’aes, T., Groote, C. C., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000102 · Cited by 30
Fronto-temporal lobar degeneration: neuropathology in 60 cases
Seilhean, D., Ber, I. L., Sarazin, M., Lacomblez, L., Millecamps, S., Salachas, F., Pradat, P., Forestier, N. L., Leguern, É., Dubois, B., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0649-y · Cited by 16
Self-citationPhenotypic Variability of Familial and Sporadic Progranulin p.Gln257Profs*27 Mutation
Pires, C., Coelho, M. M., Valadas, A., Barroso, C., Pimentel, J., Martins, M., Duyckaerts, C. J., de Mendonça, A., Verdelho, A., & Miltenberger-Miltényi, G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130146 · Cited by 13
Self-citationCalvi, A., Cioffi, S., Caffarra, P., Fenoglio, C., Serpente, M., Pietroboni, A. M., Arighi, A., Ghezzi, L., Gardini, S., Scarpini, E. A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141380 · Cited by 9 · cited 1×
“However, the pathophysiological mechanism in GRN-related disorders is probably more complex, not only depending on PGRN deficit, as undetectable levels were also found in three heterozygous carriers (Calvi et al., 2015; Galimberti et al., 2016), and as one heterozygous carrier in this study had plasma PGRN level just…”
BackgroundGalimberti, D., Bertram, K., Formica, A., Fenoglio, C., Cioffi, S., Arighi, A., Scarpini, E. A., & Colosimo, C. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160073 · Cited by 4 · cited 2×
“…is probably more complex, not only depending on PGRN deficit, as undetectable levels were also found in three heterozygous carriers (Calvi et al., 2015; Galimberti et al., 2016), and as one heterozygous carrier in this study had plasma PGRN level just under the limit of normal value (68 µg/L).”
Background
Cited by
Root, J., Merino, P., Nuckols, A., Johnson, M., & Kukar, T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105360 · Cited by 238
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111
Huang, M., Modeste, E., Dammer, E., Merino, P., Taylor, G., Duong, D. M., Deng, Q., Holler, C. J., Gearing, M., Dickson, D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01037-x · Cited by 103
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy
Specchio, N., Ferretti, A., Trivisano, M., Pietrafusa, N., Pepi, C., Calabrese, C., Livadiotti, S., Simonetti, A., Rossi, P., Curatolo, P., et al. (2020) · Drugs · doi:10.1007/s40265-020-01440-7 · Cited by 78
Metadata
- Authors
- Huin, V., Barbier, M., Bottani, A., Lobrinus, J. A., Clot, F., Lamari, F., Chat, L., Rucheton, B., Fluchère, F., Auvin, S., Myers, P., Gelot, A., Camuzat, A., Caillaud, C., Jornéa, L., Forlani, S., Saracino, D., Duyckaerts, C., Brice, A., Durr, A., & Le Ber, I.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University Hospital of Geneva (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Aix-Marseille Université (FR)
- Medical Office, Geneva, Switzerland
- Neuropathology, Department of Pathology, Trusseau Hospital, AP-HP, Paris, France and INMED INSERM U901 Luminy Campus, Aix-Marseille University, France
- Hôpital Necker-Enfants Malades (FR)
- Sorbonne Université, Institut du Cerveau et de la Moelle épinière (ICM), AP-HP, INSERM, CNRS, University Hospital Pitié-Salpêtrière, Paris, France
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-19
- Volume
- 143
- Issue
- 1
- Pages
- 303-319
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2996162164
- Cited by
- 96
- References
- 53
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 9 · 2023: 14 · 2022: 12 · 2021: 17 · 2020: 16
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- arXiv (Cornell University) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- arXiv (Cornell University)
- Funders
- VERUM (ANR-11-INBS-0011 – NeurATRIS)
- Translational Research Infrastructure for Biotherapies in Neurosciences
- Programme Hospitalier de Recherche Clinique
- PHRC
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- GRN mutations, progranulin, frontotemporal dementia, TDP-43, lysosomal storage disease, phenotypic variability, age of onset, splice site mutation, neuropathology, semidominant inheritance, genetic counseling, molecular diagnosis
- MeSH terms
- Progranulins, Adolescent, Adult, Cerebellar Ataxia, Child, Epilepsy, Female, Heterozygote, Homozygote, Humans, Male, Middle Aged, Mutation, Neuronal Ceroid-Lipofuscinoses, Retinitis Pigmentosa, RNA Splicing, Age of Onset, Parkinsonian Disorders, Rare Diseases, Young Adult, TDP-43 Proteinopathies, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.